GenomeDX Gets New Funding

San Diego-based GenomeDX Biosciences said this morning that it has raised a Series B financing round, for the company's genomic tests for prostate cancer. The funding was led by Merck Global Health Innovation Fund (GHIF), and also included Baird Capital Partners, aeris CAPITAL AG and CD Ventures. Size of the funding was not announced. The company said it will use the funding to expand commercialization of its first product, a genomic test for predicts the risk of developing metastatic prostate cancer. More information »